The potential to reconstitute the whole erythropoiesis of a genetically anemic (WB x C57BL/6)F1-W/W (WBB6F1W/WV) mouse for at least 8 weeks was compared between 5-fluorouracil (5FU)-treated and nontreated bone marrow cells. C57BI/6 Pgk 1b/Pgk 1 female mice, in which each stem cell had either A-type or B-type phosphoglycerate kinase (PGK) owing to the random inactivation of one of two X chromoso...

The role of intra-host genetic diversity in dengue viral populations remains a topic of debate, particularly the impact on transmission of changes in this diversity. Several approaches have been taken to increasing and decreasing the genetic diversity of populations of RNA viruses and have drawn what appear to be contradictory conclusions. A 2-6 fold increase in genetic diversity of a wild type...

Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5FU), and it is suggested that patients with a partial deficiency of this enzyme are at risk from developing a severe 5FU-associated toxicity. In this study, we demonstrated that a lethal toxicity after a treatment with 5FU was attributable to a complete deficiency of DPD. Analysis...

ONHERITABLE repair of a mutant phenotype resulting from errors in translation was first described by BENZER and CHAMPE (1961) for rZZ mutants of phage T4. These mutants are ordinarily unable to grow on Escherichia coli strain KB, but can grow on strain B. Treatment of infected KB cells with 5-fluorouracil (5FU) resulted in a large increase in phage yield with certain rZZ mutants, yet the progen...

To the Editor—In the February issue of Hong Kong Medical Journal, Yeo et al1 reported an informative study on the use of S-1 as adjunct chemotherapy after curative resection of gastric cancer. Since the active ingredient in S-1 is the prodrug tegafur, to be converted to 5-fluorouracil (5FU), much of the toxicity reduction depends on the degradation of 5FU by dihydropyrimidine dehydrogenase (DPD...

Agents such as the antimetabolites 5-fluorouracil (5FU) and mitomycin-C (MMC) have revolutionised glaucoma surgery in patients with a high risk of surgical failure. However, vision threatening complications can be associated with the use of these agents. Changes in antimetabolites application during and after the surgery can increase the safety and reduce the complications while maintaining eff...

Cellulose and chitosan with remarkable biocompatibility sophisticated physiochemical characteristics can be a new dawn to the advanced drug nano-carriers in cancer treatment. This study aims synthesize layer-by-layer bionanocomposites from rice straw cellulose encapsulated 5-Fluorouracil (CS-CF/5FU BNCs) using ionic gelation method sodium tripolyphosphate (TPP) cross-linker. Data X-ray Fourier-...

Great advances have been made in the past 10 years in the management of metastatic colorectal cancer (MCC). Median overall survival has improved from approximately 6 months with best supportive care, to 10–12 months with 5FU monotherapy, to more than 20 months with current regimens. Much of this progress stems from the addition of new cytotoxic and biologic agents to the medical oncologist’s ar...

BACKGROUND While ribavirin mono-therapy regimens have minimal effect on patients with chronic hepatitis C virus (HCV) infections, they can be efficacious when combined with interferon. Clinical studies show that interferon-free combination therapies containing ribavirin are also efficacious, suggesting that an interferon-free therapy could be adopted in the near future. However, generation of d...

See related article by Curreri et al., Cancer Res 1958:18: 478–484. The 1950s saw the rise of rational drug design to target DNA synthesis in cancer cells. The concept was simple; cancer was replicating uncontrolled compared with normal tissues, so this characteristic was to be its vulnerability. The momentum for rational drug design targeting DNA increased with the study by Watson and Crick of...